Here in the U.S., many startups are facing hard questions about how they’ve grown: bloated valuations, misaligned incentives, shallow product pipelines. The contrast with Korea’s quiet biotech ascent ...

The workplace shouldn’t require you to separate who you are at work from who you are at home. Instead of work-life balance, ...

First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M ...

Orchestra BioMed holds two best-in-class medical device therapies targeting large markets. Find out why OBIO stock is a Buy.

As industries evolve, so does the demand for diverse leadership. From technology to sustainability, these nine career paths ...

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement ...

The custom-built gene editing treatment for 6-month-old KJ Muldoon could not have come at a more welcome or jarring time for ...

Job cuts at home-grown pharma companies like Arvinas and RallyBio and federal policies challenge CT biotech 'ecosystem' that ...